Acute heart failure (AHF) is a sudden and life-threatening condition in which the heart is unable to pump blood efficiently, leading to rapid onset of symptoms such as shortness of breath and fluid retention. As per the CDC estimates, it accounts for around one million hospitalizations annually in the United States. According to the acute heart failure pipeline analysis by Expert Market Research, the market is witnessing steady growth due to increasing R&D investments, novel drug developments, and the growing focus on targeted acute heart failure therapeutics. Rising global prevalence and technological advancements are expected to drive further growth in the coming years.
Major companies involved in the acute heart failure pipeline analysis include Boehringer Ingelheim, Bayer, and others.
Leading drugs currently in the pipeline include SGLT2 Inhibitor, CardiolRx, and others.
The acute heart failure drug pipeline is expanding due to increased clinical trials for novel cardioprotective agents and rising investment in peptide-based therapeutics and gene-modulating therapies.
The Acute Heart Failure Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute heart failure therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute heart failure. The acute heart failure report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute heart failure pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute heart failure treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute heart failure.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acute heart failure is a sudden and severe onset of heart failure symptoms due to the heart's inability to pump blood effectively. It often occurs when preexisting heart conditions worsen, leading to fluid buildup in the lungs or other organs. Triggers may include a heart attack, arrhythmia, or uncontrolled hypertension, requiring urgent medical attention.
Acute heart failure treatment focuses on stabilizing the patient and relieving symptoms. It typically involves intravenous diuretics, vasodilators, oxygen therapy, and in some cases, inotropes or mechanical support. In the acute heart failure drug pipeline, Vericiguat (Verquvo), a soluble guanylate cyclase stimulator, is being evaluated for reducing cardiovascular death or heart failure hospitalization in patients with worsening heart failure.
Acute heart failure (AHF) continues to pose a growing global health burden. In 2021, 56.5 million heart failure cases were reported worldwide, with 27.3 million in women and 29.2 million in men. In the United States, 6.7 million adults had heart failure, contributing to 13.9% of deaths in 2022. In India, heart failure affects about 1% of the population, with incidence expected to rise by 18% by 2025, particularly among younger patients with type 2 diabetes.
This section of the report covers the analysis of acute heart failure drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III accounts for 35.19%, covering a major share of the total acute heart failure clinical trials. Phase IV also holds 35.19%, reflecting robust post-marketing studies. Phase II represents 24.07%, while Phase I and Early Phase I contribute 3.70% and 1.85%, respectively. This balanced pipeline supports continued innovation and potential breakthroughs in treatment options.
The drug molecule categories covered under the acute heart failure pipeline analysis include small molecules, monoclonal antibodies, peptides, RNA-based therapies, stem cells, and others. The acute heart failure report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute heart failure.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are gaining attention in the management of acute heart failure. For instance, dapagliflozin, originally approved for type 2 diabetes, has shown promising results in improving diuresis and reducing hospital stays when administered within 24 hours of admission. Its dual action supports both fluid elimination and early initiation of outpatient heart failure therapy.
The EMR report for the acute heart failure pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed acute heart failure therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in acute heart failure clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute heart failure. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute heart failure drug candidates.
SGLT2 inhibitors, including empagliflozin and dapagliflozin, are being studied in a Phase 3 trial sponsored by National Taiwan University Hospital. The study aims to evaluate their role in reducing cardiac ischemia and cardiopulmonary edema during ventilator weaning in acute decompensated heart failure (ADHF) patients. These drugs, by enhancing urinary glucose and sodium excretion, are potentially supporting hemodynamic stability and reducing fluid overload during critical respiratory transitions.
CardiolRx™, sponsored by Cardiol Therapeutics, is currently undergoing a Phase II randomized, double-blind, placebo-controlled clinical trial (ARCHER) to assess its effect on myocardial recovery in patients with acute myocarditis. This cannabidiol-based oral therapy is being evaluated for its anti-inflammatory and anti-fibrotic properties. The study aims to examine improvements in cardiac function and tissue inflammation using advanced cardiac MRI, targeting a patient population with no currently approved treatments.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Acute Heart Failure Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute heart failure. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute heart failure collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share